Medicare evaluating coverage for $56,000 Alzheimer’s drug

Jul 12, 2021, 3:32 PM | Updated: 4:50 pm

WASHINGTON (AP) — Medicare on Monday launched a formal process to decide whether to cover Aduhelm, the new Alzheimer’s drug whose $56,000-a-year price tag and unproven benefits have prompted widespread criticism and a congressional investigation.

A final decision isn’t likely until next spring, said the Centers for Medicare and Medicaid Services, or CMS, although an initial ruling could come in six months. Currently Medicare is making case-by-case determinations on whether to cover the medication, which is administered intravenously in a doctor’s office.

Medicare’s announcement came on the same day that Democratic leaders of two House committees asked drugmaker Biogen to turn over reams of documents on how it developed and priced the drug, and on its dealings with government officials at the Food and Drug Administration.

Although pricey drugs are now fairly commonplace, the recent approval of Aduhelm prompted an unusually intense backlash. The FDA went against the recommendation of its outside advisers in granting the approval, and the beleaguered agency has since curtailed the recommended use of the drug and requested an investigation by an independent watchdog into its dealings with Biogen. Meanwhile, Democrats in Congress are moving legislation authorizing Medicare to negotiate drug prices.

CMS Administrator Chiquita Brooks-LaSure signaled that neither politics nor cost will be part of Medicare’s evaluation.

“We want to consider Medicare coverage of new treatments very carefully in light of the evidence available,” Brooks-LaSure said in a statement that acknowledged the toll of Alzheimer’s disease on patients and their families. “Our process will include opportunities to hear from many stakeholders, including patient advocacy groups, medical experts, states, issuers, industry professionals, and family members and caregivers of those living with this disease.”

A 30-day public comment period began Monday, followed by two hearings to solicit a range of views. The agency’s decision will hinge on whether the evidence for Aduhelm meets a legal requirement that covered services, medical devices and medications be “reasonable and necessary for the diagnosis or treatment of illness or injury.”

Lawmakers, meanwhile, intensified their scrutiny of the drug’s approval.

Two committees in the House asked Biogen to hand over documentation on a number of issues surrounding the development of Aduhelm, including unusual contacts between company executives and FDA regulators.

Biogen and the FDA reanalyzed Aduhelm’s data together after the company’s studies suggested the drug was ineffective at slowing mental decline. The collaboration ultimately led to the FDA granting conditional approval for the drug, against the advice of its outside experts.

In particular, the lawmakers ask Biogen to turn over details about a company initiative dubbed “Project Onyx, to persuade FDA to approve Aduhelm.”

Last week, the FDA asked the government’s independent watchdog to investigate unusual interactions between some FDA staffers and Biogen. That included reports of at least one “off the books” discussion between a Biogen executive and the FDA’s top Alzheimer’s drug reviewer.

Meetings between drug industry representatives and the FDA are normally carefully scheduled and documented. The FDA’s acting commissioner, Dr. Janet Woodock, asked the inspector general for the Department of Health and Human Services to probe whether the agency’s dealings with Biogen violated any government rules.

Another large part of the lawmakers’ request involves documents detailing how Biogen arrived at the drug’s price, pegged at roughly $56,000 for the typical patient. The drug requires monthly IVs and the dosage is based on a patient’s weight.

The committee chairs noted that a nonprofit think tank focused on drug pricing pegged the drug’s actual value at between $3,000 and $8,400 per year, based on its unproven benefits.

“While the company has claimed this price is ‘fair’ and ‘substantiated by the value it is expected to bring,’ an independent analysis determined that a fair price for Aduhelm would be a small fraction of Biogen’s price,” said committee chairs Rep. Carolyn Maloney and Rep. Frank Pallone.

Maloney heads the Committee on Oversight and Reform, and Pallone heads the Committee on Energy and Commerce.

The letter instructs Biogen to turn over the information by July 26.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

AP

A students joins Indigenous women in a rally to show support for the recent protests and national s...
Associated Press

Ecuador president cuts gasoline price amid Indigenous strike

QUITO, Ecuador (AP) — Ecuadorian President Guillermo Lasso announced a cut in gasoline prices Sunday that appeared to fall short of the reduction demanded by Indigenous leaders to end a strike that has paralyzed parts of the country for two weeks. The reduction cuts the price of gasoline by 10 cents per gallon. The Confederation […]
23 hours ago
FILE - Republican candidate for Illinois governor Richard Irvin speaks with employees during a tour...
Associated Press

What to watch in primaries in Colorado, Illinois, elsewhere

NEW YORK (AP) — Seven states are set to host primary elections Tuesday as the nation comes to terms with last week’s stunning Supreme Court ruling eliminating the constitutional right to an abortion. This week’s nominating contests could offer the first clues as to whether the political landscape has shifted. Abortion is particularly relevant in […]
23 hours ago
FILE - Andrew Giuliani, left, a Republican candidate for Governor of New York, is joined by his fat...
Associated Press

Andrew Giuliani invokes famous dad in bid for NY governor

NEW YORK (AP) — After 2020, Rudy Giuliani is not someone most politicians would summon to hold a news conference on their behalf. As the frontman of former President Donald Trump’s false claims of election fraud, Giuliani made notorious appearances before cameras where he espoused baseless theories — once while doing an impression of actor […]
23 hours ago
Associated Press

Home prices, General Mills earns, consumer spending

A look at some of the key business events and economic indicators upcoming this week: HOME PRICE MONITOR A limited inventory of homes for sale coupled with strong demand has helped keep U.S. home prices climbing sharply. S&P’s CoreLogic Case-Shiller home price index tracks the value of homes in 20 major U.S. metropolitan areas. It […]
23 hours ago
FILE - A person waits in line to vote in the Georgia's primary election on May 24, 2022, in Atlanta...
Associated Press

More than 1 million voters switch to GOP in warning for Dems

WASHINGTON (AP) — A political shift is beginning to take hold across the U.S. as tens of thousands of suburban swing voters who helped fuel the Democratic Party’s gains in recent years are becoming Republicans. More than 1 million voters across 43 states have switched to the Republican Party over the last year, according to […]
23 hours ago
President Joe Biden, right, walks with European Commission President Ursula von der Leyen, center, ...
Associated Press

Tale of 2 summits: ‘America’s back’ to America’s backsliding

ELMAU, Germany (AP) — One year ago, Joe Biden strode into his first Group of Seven summit as president and confidently told the closest U.S. allies that “America is Back.” Now, many of them are worrying that America is backsliding. As Biden meets this week in the Bavarian Alps with the heads of G-7 leading […]
23 hours ago

Sponsored Articles

(Courtesy Condor)...
Condor Airlines

Condor Airlines shows passion for destinations from Sky Harbor with new-look aircraft

Condor Airlines brings passion to each flight and connects people to their dream destinations throughout the world.
...
Carla Berg, MHS, Deputy Director, Public Health Services, Arizona Department of Health Services

Update your child’s vaccines before kindergarten

So, your little one starts kindergarten soon. How exciting! You still have a few months before the school year starts, so now’s the time to make sure students-to-be have the vaccines needed to stay safe as they head into a new chapter of life.
...
Christina O’Haver

BE FAST to spot a stroke

Every 40 seconds—that’s how often someone has a stroke in the United States. It’s the fifth leading cause of death among Americans, with someone dying of a stroke every 3.5 minutes.
Medicare evaluating coverage for $56,000 Alzheimer’s drug